ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,841 to 2,860 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI69 of 1,286

55 of 1,300

1.1 points

-0.5 to 2.8

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)63 of 1,286

48 of 1,300

1.2 points

-0.4 to 2.8

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)10 of 1,286

6 of 1,300

0.3 points

-0.3 to 1.0

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR10 of 1,286

6 of 1,300

0.3 points

-0.3 to 1.0

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)1,194 of 1,282

1,246 of 1,303

-2.5 points

-4.3 to -0.7

2,585NCT02173379

Absorb IV Randomized Controlled Trial

PPCS in Derivation vs PPCS in Validation: Count of Children Who Have Persistent Post-concussive Symptoms (PCS) at One-month Follow-up.510 of 1,701

291 of 883

-3.0 points

-6.8 to 0.8

2,584NCT01873287

Predicting Persistent Postconcussive Problems in Pediatrics (5P)

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization111 of 1,285

122 of 1,298

-0.8 points

-3.0 to 1.5

2,583NCT02173379

Absorb IV Randomized Controlled Trial

Intervention vs No Intervention: Infant Morbidity, 2 Week Diarrhoea Prevalence104 of 1,323

101 of 1,256

-0.2 points

-2.3 to 1.9

2,579NCT00397150

PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa

Peer Counselling for Exclusive Breastfeeding vs Standard of Care: serious adverse events32 of 1,323

22 of 1,256

0.7 points

-0.5 to 1.8

2,579NCT00397150

PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography33 of 1,282

40 of 1,295

-0.5 points

-1.8 to 0.8

2,577NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization178 of 1,282

178 of 1,291

0.1 points

-2.6 to 2.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)86 of 1,282

75 of 1,291

0.9 points

-1.0 to 2.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)14 of 1,282

14 of 1,291

0.0 points

-0.8 to 0.9

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)70 of 1,282

56 of 1,291

1.1 points

-0.6 to 2.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR14 of 1,282

14 of 1,291

0.0 points

-0.8 to 0.9

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization41 of 1,282

30 of 1,291

0.9 points

-0.4 to 2.2

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)80 of 1,282

67 of 1,291

1.1 points

-0.8 to 2.9

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)7 of 1,282

8 of 1,291

-0.1 points

-0.7 to 0.6

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI71 of 1,282

61 of 1,291

0.8 points

-0.9 to 2.5

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)22 of 1,282

11 of 1,291

0.9 points

-0.0 to 1.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=143"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=143

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-b7bc47c2",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI",
        "summary": "69 of 1286 against 55 of 1300; risk difference 1.1 points, 95% interval -0.5 to 2.8; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-b7bc47c2",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2586,
        "risk_difference": {
          "value": 0.011347051082665385,
          "lower": -0.00522327363854188,
          "upper": 0.028109032145895628
        },
        "group_1": "69 of 1,286",
        "group_2": "55 of 1,300",
        "difference": "1.1 points",
        "interval": "-0.5 to 2.8",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-bca9d2ec",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)",
        "summary": "63 of 1286 against 48 of 1300; risk difference 1.2 points, 95% interval -0.4 to 2.8; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-bca9d2ec",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2586,
        "risk_difference": {
          "value": 0.01206603660724967,
          "lower": -0.003655949335341066,
          "upper": 0.028019915896927677
        },
        "group_1": "63 of 1,286",
        "group_2": "48 of 1,300",
        "difference": "1.2 points",
        "interval": "-0.4 to 2.8",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=144",
  "request_id": "Cxrva1uqnUpNKH5J"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?